Evidence mapPaperPMID 41103532Full record

ReviewOncology letters2025

Pathogenic role and therapeutic targets of nuclear factor-κB signaling pathway in cancer (Review).

Xing Li, Lu Chen, Ming Zeng, Jialun Deng, Fan Chen, Lingying Yu, Mingyue Ao

Abstract readReview
In one paragraph

Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xing LiDepartment of Pharmacy, Jianyang Chinese Medicine Hospital, Chengdu, Sichuan 641499, P.R. China.
Lu ChenDepartment of Pharmacy, Jianyang Chinese Medicine Hospital, Chengdu, Sichuan 641499, P.R. China.
Ming ZengDepartment of Pharmacy, Jianyang Chinese Medicine Hospital, Chengdu, Sichuan 641499, P.R. China.
Jialun DengDepartment of Pharmacy, Jianyang Chinese Medicine Hospital, Chengdu, Sichuan 641499, P.R. China.
Fan ChenDepartment of Pharmacy, Jianyang Chinese Medicine Hospital, Chengdu, Sichuan 641499, P.R. China.
Lingying YuDepartment of Pharmacy, China State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.
Mingyue AoResearch Center of Traditional Chinese Medicine, Yunnan Research Institute of Traditional Chinese Medicine, Kunming, Yunnan 650051, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nuclear factor-κB (NF-κB) signaling pathway not only exerts a notable role in inflammation and immune modulation but is also considered a key driver in the initiation and progression of cancer. NF-κB is closely associated with tumor cell proliferation, differentiation, apoptosis, invasion and metastasis, indicating its notable role in cancer pathogenesis. Based on research into the NF-κB pathway, the present article studied the biochemical processes involved in the NF-κB pathway, analyzed potential drug targets and inhibitors and clarified therapeutic strategies for targeting NF-κB in cancer treatment. The NF-κB signaling pathway consists of both classical and non-classical pathways and plays a fundamental role in multiple cancer processes, including cancer cell proliferation, apoptosis, autophagy, inflammation, tumor microenvironment interactions, therapy resistance, ion channel modulation, tumor heterogeneity, and epithelial-mesenchymal transition (EMT)-mediated migration, invasion and metastasis. Current therapeutic development has yielded diverse pharmacological agents targeting this pathway, including phytochemical-derived NF-κB inhibitors and synthetic molecules for cancer therapy.

Indexed as

biochemical processescancerdrugsinhibitorsnuclear factor-κB pathway

Identifiers

PMID41103532
PMCPMC12521888

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.